The Company’s Current Operating
Quarter is Its 2nd Fiscal Quarter 2022 (Period:
July 1, 2021 – September 30, 2021)
NEW YORK, NY -- August 3, 2021 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a New York based diversified Life
Sciences Company, has today confirmed that it’s on pace for a
strong Quarter from its retail business. The Company’s
current operating Quarter is its 2nd Fiscal Quarter
2022 (Period: July 1, 2021 – September 30, 2021). During the
month of July 2021, the Company has experienced acceleration in
both demand and interest, for its enhanced products and product
lines as well as its innovative, newly introduced, product
offerings. The Company has also been successful in
integrating cost saving measures into its manufacturing processes,
without even the slightest compromise of quality.
For Month of July 2021: Net Revenue Exceeded $60,000
The Company’s enhanced Tauri-Gum™ product line (its flagship
brand) has been well received by both existing E-Commerce customers
as well as prospective retail customers (of all sizes). The
Company is confident in the competitiveness of its established
wholesale pricing, which preserve solid “built in” gross margins
for its future anticipated revenue growth.
Additionally - The Company is excited about the commercial
launch of its innovative, Delta 8 THC (10mg) infused chewing gum;
Evergreen Mint Flavor version of Tauri-Gum™.
With inventory now available for all of its products and
enhanced product lines, the Company will be focused on meaningfully
growing its revenue and continually acquiring new
customers. There are many exciting corporate initiatives
that are currently underway and the Company looks forward to
updating its shareholders as material progress is
realized.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C
+ Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused
Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused
Tauri-Gum™ Flavor: Golden Raspberry). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 22, 2021, the Company announced that it had
Converted its U.S. Provisional Patent Application (filed on March
17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates two full time
E-Commerce fulfillment centers: one located in Montgomery, Texas
and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024